(Total Views: 553)
Posted On: 08/26/2020 10:51:31 AM
Post# of 153991
Re: enemyofpluto #52317
The standard of care is whatever the trial site institution has adopted. Obviously the standard of care has and continues to evolve.
This is part of why trials need to be both blinded and randomly assigned, so that Leronlimab, not variation among institutional standard of care is the determining factor in patient outcome.
Multiple care factors impact outcome.
Steroids
Remdesivir (maybe)
Early vs late intubation
Supine versus prone postioning
Prophylactic low molecular weight heparin (all patients or risk factors for coagulopathy?), LMWH by the way is anti-inflammatory as we as anticoagulant.
Il-6 blockers
Conv therapy
All these potentially confounding factors (some may have no effect, some help and some hurt) are part of the reason trials need many patients, in addition to sufficient size to demonstrate statistically significant results so that conclusions can be made with confidence.
This is part of why trials need to be both blinded and randomly assigned, so that Leronlimab, not variation among institutional standard of care is the determining factor in patient outcome.
Multiple care factors impact outcome.
Steroids
Remdesivir (maybe)
Early vs late intubation
Supine versus prone postioning
Prophylactic low molecular weight heparin (all patients or risk factors for coagulopathy?), LMWH by the way is anti-inflammatory as we as anticoagulant.
Il-6 blockers
Conv therapy
All these potentially confounding factors (some may have no effect, some help and some hurt) are part of the reason trials need many patients, in addition to sufficient size to demonstrate statistically significant results so that conclusions can be made with confidence.
(3)
(0)
